Targeting a novel inducible isoform to treat metabolic-associated fatty liver disease
Metabolic-associated fatty liver disease (MAFLD), which was previously known as non-alcoholic fatty liver disease (NAFLD), represents a major health concern worldwide with limited therapy. The authors of an article, recently ...